Clinical trials: Circulating Tumor Cell;
Non-small Cell Lung Cancer
ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy
The goal of this observational study is to explore whether ctDNA-MRD dynamic monitoring can more effectively predict the therapeutic effect of induction chemoimmunotherapy followed by surgery or non-surgical treatment for stage…
- Trial name
- NCT05822284
- Testing
- NGS and ctDNA-MRD detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Xiangya Hospital of Central South University
Neuroendocrine Tumors
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)
Prospective, multicentric, single arm, POC study to evaluate the value of CtDNA in follow-up of patients treated with everolimus, with or without somatostatin analogues for advanced gastroenteropancreatic or lung neuroendocrine…
- Trial name
- NCT05268952
- Testing
- Liquid biopsies, Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)
- Where
- 3 sites in Belgium, Cyprus
- Volunteers
- 100 people
- Sponsor
- University Hospital, Antwerp
Melanoma
ctDNA for Early Detection of Recurrence in Melanoma
This study examines circulating tumor DNA (ctDNA) as a biomarker for early detection of recurrence in high-risk patients, following treatment of primary melanoma.
- Trial name
- NCT06246227
- Where
- Denmark
- Volunteers
- 467 people
- Sponsor
- Herlev and Gentofte Hospital
Lung Cancer
Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients
This is a prospective pilot study designed to demonstrate the impact of circadian rhythm on the spread of Circulating Tumor Cells (CTCs) in patients with Non- Small Cell Lung Cancer - NSCLC.
- Trial name
- SLEEP_CTC (NCT05988970)
- Testing
- Blood samples will be collected at two times before the treatment initiation:
- Where
- 2 sites in France
- Volunteers
- 27 people
- Sponsor
- Institut Claudius Regaud
Patients With Non-small Cell Lung Cancer
Development of Circulating Tumour Cell Molecular Diagnostics Using a Novel Microfluidic Device
1. To compare EGFR mutations between primary non-small cell lung cancer (NSCLC) tumours and corresponding CTCs isolated by a label-free microfluidic device-based system 2.
- Trial name
- NCT01193829
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Breast Neoplasms, Circulating Tumor Cells
Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device
Circulating tumor cells (CTCs) in peripheral blood originate from breast cancer (primary and metastatic lesions) shedding. Utilization of CTCs as novel and noninvasive tests for diagnosis confirmation, therapy selection, and…
- Trial name
- NCT04239105
- Testing
- Microfluidic and Raman spectrum
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
This phase II trial studies how well using circulating tumor deoxyribonucleic acid (DNA) to guide lower dose radiation therapy works in treating patients with human papillomavirus infection (HPV)-associated oropharyngeal cancer.
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06323460
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Colorectal Cancer (Diagnosis), Non-cancer Controls
Epigenetic Signature for CRC Early Detection
The epiCED is a noninvasive blood-based assay designed for early detection of colorectal cancer (CRC) using circulating cell-free DNA (cfDNA) 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) epigenetic markers.
- Conditions
- Colorectal Cancer (Diagnosis), Non-cancer Controls, DNA Methylation, Cell Free DNA
- Trial name
- epiCED (NCT07224854)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Prostate Cancer Metastatic
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The aim of the study is to assess the clinical utility of 11C or 18F-Choline Positron Emission Tomography (PET)/Computed Tomography (CT) scan, Whole Body Magnetic Resonance Imaging (MRI) versus conventional bone scan and…
- Trial name
- NCT02815033
- Testing
- Enzalutamide, 11C or 18F-Choline PET/CT, Whole body MRI
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- The European Uro-Oncology Group
Neoplasms, Cancer
The Circulating Cell-free Genome Atlas Study
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood.
- Trial name
- CCGA (NCT02889978)
- Where
- 140 sites in United States, Canada
- Volunteers
- 15,254 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Circulating Tumor Cells (CTCs)
Collection of Circulating Tumor Cells From the Peripheral Blood of Metastatic Breast Cancer Patients
To address the challenges of isolating and analyzing rare cells, this study aims to validate the instrumentation, the test protocols, and the analysis of patient's outcome to show the instrument's capability to reproducibly and…
- Trial name
- NCT02904135
- Where
- Taiwan
- Volunteers
- 141 people
- Sponsor
- MiCareo Taiwan Co., Ltd.
Lung Cancer
Circulating Tumor Cells Spillage After Pulmonary Biopsy
The aim of this study is to quantify the spillage of tumor cells after biopsy in early lung cancer.
- Trial name
- NCT02507778
- Testing
- CellCollectorTM (Gilupi, Germany) needle
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rabin Medical Center
Non-small Cell Lung Cancer
Analysis of Soluble Mediators,Cytokines and FACs as Prognostic Factors in Advanced Non-squamous Lung Carcinoma
Recent studies have shown that the assessment of a set of cytokines and / or circulating angiogenic factors (FACs) could be used to identify prognostic factors predictive of efficacy and / or potential mechanisms of resistance to…
- Trial name
- NCT03156868
- Where
- 25 sites in Spain
- Volunteers
- 153 people
- Sponsor
- Spanish Lung Cancer Group
Metastatic Colorectal Cancer
Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients
Aim of the present study is to investigate whether baseline or early post-treatment (one month after treatment commencement) frequency of peripheral T regulatory lymphocytes (Tregs OR CD4+/CD25high/FOXP3+ T cells), known to…
- Trial name
- NCT01533740
- Testing
- fluorouracil/irinotecan/levo-folinic acid/bevacizumab
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- University of Rome Tor Vergata
Colorectal Cancer and Melanoma
Circulating Tumor Material in Colorectal Cancer and Melanoma
Observational study to allow the collection of blood and medical information to evaluate the role of circulating tumor material in patients with colorectal cancer and melanoma
- Trial name
- NCT02907086
- Testing
- blood collection
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non Small Cell Lung Cancer
Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC
The study aim to evaluate whether some substances produced by muscle or adipose tissue may play a role in the course of the disease by interfering with the effectiveness of therapies.
- Trial name
- SARCLUNG (NCT06808113)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Melanoma
Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy
The goal of this clinical trial is to investigate adaptive therapy in late-stage cutaneous melanoma. The main question it aims to answer are: If the patient having breaks in their treatment allows the less resistant cells to…
- Trial name
- DyNAMIc (NCT06470880)
- Testing
- Adaptive Therapy, Standard of Care
- Volunteers
- 40 people
- Sponsor
- The Christie NHS Foundation Trust
Adenocarcinoma of the Prostate
Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer
CTC-STOP is a multicentre prospective randomised controlled phase III trial for metastatic castration-resistant prostate cancer patients.
- Trial name
- CTC-STOP (NCT03327662)
- Testing
- Active CTC Assessment
- Where
- 4 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Carcinoma, Renal Cell, Carcinoma, Urothelial
Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)
This pilot study purpose of this study is to describe peripheral circulating immune cell profiles at baseline and change on treatment with immune checkpoint inhibitors in renal cell carcinoma and urothelial carcinoma.
- Trial name
- NCT02978118
- Testing
- Immune cell and CTC detection procedures
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Duke University
Lung Cancer, Non Small Cell Lung Cancer
Optimizing Endobronchial Ultrasound Sampling for Molecular Markers for NSCLC
In this monocentric randomized controlled trial, 120 potential non small cell lung cancer (NSCLC) patients for which tissue diagnosis and material for next generation sequencing (NGS) is required for clinical management will be…
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Circulating Tumor Cell
- Trial name
- OPTIMAL (NCT05560776)
- Testing
- Endobronchial ultrasound
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval